Stallion India Fluorochemicals (STALLION) — Annual Report

📢 Key Event
Stallion India Fluorochemicals Limited filed its FY 2025-26 Annual Report with NSE and BSE, highlighting financial performance, rights issue, and AGM notice.

🔄 What Changed
Revenue grew 14.40% to ₹43,067.80 lakhs; PAT rose 35.61% to ₹4,384.11 lakhs; no dividend declared; rights issue completed raising ₹363.92 crores.

🔮 What's Next
The company plans to invest ₹200 crores in a new HFO manufacturing facility in Bhilwara, Rajasthan, and expand helium recovery capabilities through partnerships with SYS ADVANCE and Sharjah Oxygen Company.

💡 Investor Takeaway
Stallion delivered strong FY26 financial growth and capital-raising success, but chose to retain earnings rather than pay dividends, signaling reinvestment for future expansion in specialty gases and sustainable technologies.

Stallion India Fluorochemicals Limited reported FY 2025-26 revenue of ₹43,067.80 lakhs, up 14.40% YoY, with profit after tax at ₹4,384.11 lakhs, a 35.61% increase. The company declared no dividend, retained earnings for future growth, and completed a rights issue raising ₹363.92 crores at ₹99 per share. Key financial highlights include EBITDA of ₹6,134.74 lakhs (14.13% margin), strong net worth growth to ₹68,060.35 lakhs, and robust cash generation. The Board highlighted strategic investments in HFO and helium recovery technologies, expansion plans in Rajasthan and Andhra Pradesh, and compliance with ESG initiatives. No material risks were identified beyond regulatory compliance and market volatility.

📄 View Original Announcement (PDF)

📊 Stock Analysis — STALLION ✨ Ask AI About This

About Stallion India Fluorochemicals Ltd (STALLION)

Chemicals · Chemicals · Listed on BSE

Market Cap: ₹2,445.35 Cr P/E: 36.5 ROE: 17.3% ROCE: 23.3%

View full STALLION stock details →

📡 Get AI alerts when STALLION files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track STALLION — Free

💡 Ask AI about this filing

"What is the expected timeline for the new HFO facility in Bhilwara to become operational?" "How will the rights issue funds be allocated across working capital, capex, and general corporate purposes?" "What specific risks does the company identify around foreign exchange volatility given its 726.60 lakhs USD-denominated liabilities?"

Ask AI Free →

📊 More STALLION filings

See all STALLION filings →

🔥 Also filed on 29 August 2026

AARTIPHARM Aarti Pharmalabs Ltd Annual Report FUSION Fusion Finance Ltd Corporate Action AKSHARCHEM AksharChem (India) Ltd Corporate Action SPAL S P Apparels Ltd Insider Trading DHARMAJ Dharmaj Crop Guard Ltd Annual Report 512271 Tashi India Ltd Annual Report

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when STALLION files new disclosures

Track STALLION filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track STALLION — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd